Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
3 pending office actions • 3 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Akeso Pharmaceuticals, Inc. maintains a portfolio in the Biotechnology & Pharmaceuticals sector with 3 pending office actions. These actions are distributed across 3 distinct examiners and 3 distinct art units, suggesting a diversified examination path despite the small number of active cases. DRISCOLL, LORA E BARNHART is the busiest examiner for the company, though they are currently responsible for only 1 pending office action.
The presence of 3 pending office actions and 3 distinct examiners indicates that each active matter is being reviewed by a different individual. Practitioners should note that the 3 pending office actions require engagement with 3 distinct sets of examiner preferences. This distribution across 3 distinct art units may require a broader range of technical arguments than a more concentrated portfolio would. The workload is evenly spread, with the busiest examiner handling only 1 pending case. This lack of concentration across 3 distinct examiners means that the applicant's success is not overly dependent on any 1 examiner's perspective.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (33%) |
| Double-patenting + other | 1 (33%) |
| Multi-statute (no §101) | 1 (33%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| DRISCOLL, LORA E BARNHART | 1 | 32.0% | +20.0% |
| AEDER, SEAN E | 1 | 57.0% | +19.9% |
| LUNDE, GRACE HENRY | 1 | 63.0% | +38.9% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18024471 | ANTI-CD47 MONOCLONAL ANTIBODY AND USE THEREOF | AEDER, SEAN E | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18264191 | THERAPEUTIC COMBINATION AND USE THEREOF | DRISCOLL, LORA E BARNHART | 28d overdue |
| 18024471 | ANTI-CD47 MONOCLONAL ANTIBODY AND USE THEREOF | AEDER, SEAN E | — |
| 17630467 | ANTI-CTLA4-ANTI-PD-1 BISPECIFIC ANTIBODY AND USES THEREOF | LUNDE, GRACE HENRY | — |
| Art Unit | Apps |
|---|---|
| 3991 | 1 |
| 1642 | 1 |
| 1641 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18264191 | THERAPEUTIC COMBINATION AND USE THEREOF | DRISCOLL, LORA E BARNHART | 3991 | §103Other | Final Rejection | 28d overdue | Pending | Aug 03, 2023 |
| 18024471 | ANTI-CD47 MONOCLONAL ANTIBODY AND USE THEREOF | AEDER, SEAN E | 1642 | §103§112Other | Final Rejection | — | Pending | Mar 02, 2023 |
| 17630467 | ANTI-CTLA4-ANTI-PD-1 BISPECIFIC ANTIBODY AND USES THEREOF | LUNDE, GRACE HENRY | 1641 | §102§103§112DP | Non-Final OA | — | Pending | Jan 26, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial